REP 2139
Alternative Names: REP 2139; REP 2139 calcium chelate; REP 2139 magnesium chelate; REP 2139-Ca; REP 2139-Mg; REP 9AC'Latest Information Update: 28 Feb 2026
At a glance
- Originator REPLICor
- Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
- Mechanism of Action Hepatitis B virus replication inhibitors; Virus replication inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B; Hepatitis D
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-B(Combination therapy, Second-line therapy or greater) in Austria (SC, Injection)
- 28 Feb 2026 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-B(Combination therapy, Second-line therapy or greater) in France (SC, Injection)
- 28 Feb 2026 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-B(Combination therapy, Second-line therapy or greater) in Israel (SC, Injection)